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The outlook for most patients with lung cancer remains bleak, with an overall five year survival rate of less than 10%. Surgery still offers the best chance of cure in the small group of patients with resectable lesions. The life span of patients with small cell tumours has been extended by combination chemotherapy but long term survival is rare. Nearly all patients are therefore treated with palliative intent.
The outcome of treatment has traditionally been measured in terms of the extent and duration of tumour response and the patient's survival time. In the absence of major therapeutic advances in the past decade, differences between treatments as measured by these biological indices have been small and it has become increasingly relevant to compare the cost (in terms of morbidity) at which any gain is achieved. The psychosocial issues raised by the disease and its treatment have recently been comprehensively reviewed.'2 Scales for monitoring toxicity related to treatment3 and performance status" are widely used but inadequate for assessing some key aspects of patients' experience-for example, pain and nausea-that are essentially subjective. Furthermore, .clinical experience shows that patients with apparently similar performance status and toxicity may experience substantially different quality of life. Although good clinicians consider quality of life as an important variable, most also regard it as a matter of clinical judgement: the "art" as opposed to the "science" of medicine. These assessments are unsystematic and subjectively biased and more reproducible methods are required for use in (1) auditing clinical practice, (2) evaluating treatment outcome in clinical trials, (3) informed decision making in the care of individual patients, (4) justifying needs for supportive services, and (5) allocating resources for medical services.
Vigorous research efforts by clinicians and social scientists over the past decade have resulted in a bewildering array of quality of life measures, but only by sustained collaboration can the reliability and validity of these instruments be ascertained and common problems in data collection and analysis overcome. Those There are surprisingly few reports of quality of life measurements in patients undergoing treatment for lung cancer. The increasing use of chemotherapy for small cell tumours and more recently for non-small cell lung cancer has stimulated most interest in this subject.
CHEMOTHERAPY
Many early studies of chemotherapy in small cell lung cancer included assessment of functional performance as an attempt to measure the quality of life.9"" Most reported an association between improved scores and response to treatment, though one study'5 suggested that subsequent maintenance treatment was accompanied by a fall in performance scores. Coates et al7 also attempted to assess quality of life by means of a linear analogue self assessment scale, measuring general wellbeing and other specific factors (mood, pain, nausea, vomiting, appetite, breathlessness, and physical activity) and showed a good correlation with performance ratings on the ECOG scale.
The intensity of performance scores for detecting changes in quality of life in lung cancer was highlighted in a recent study'8 that compared three different instruments (diary cards, the EORTC questionnaire, and the quality of life index of Spitzer et al) in a small group of patients enrolled in a randomised trial of duration of chemotherapy in small cell lung cancer. The diary cards showed a worsening of quality of survival as treatment continued, which was not seen with the Karnofsky scores. The comparisons between the three quality of life instruments showed the appropriate convergent and divergent validity and showed that the diary cards were more sensitive to short term changes.
Non-small cell lung cancer is a less chemosensitive disease, but for the small proportion of patients who might benefit from this form of treatment would seem a rational choice as most patients have metastatic disease at presentation. In a recent review of the role of chemotherapy in advanced non-small cell lung cancer'9 Splinter commented that few of the 142 published studies attempted to measure quality of life. In most, the response to treatment correlated with improvement in physical performance, but in others no change was seen and in some40" quality of life as measured by Karnofsky index fell during treatment. The study reported by Bakker et al"' deserves comment. It assessed the effects of three drugs (vindesine, cisplatin, and bleomycin) in an uncontrolled group of relatively fit patients. The authors reported a high response rate (48%), with a median survival of 47 weeks in those responding, but concluded that the fall in performance duringtreatmentoffsetthe benefits of treatment.
Most studies of chemotherapy in non-small cell lung cancer show only a small survival advantage in responding patients and very few have compared active treatment with the best supportive care.39 As only palliation can be expected there would appear to be a strong case for including measurements of quality of life in any future studies.
RADIOTHERAPY
Although radiotherapy is recognised as being capable of effectively palliating symptoms in patients with lung cancer, little is known of its impact on other aspects of a patient's life. In two studies of combined chemotherapy and radiotherapy in small cell lung cancer3738 the periods of radiotherapy were associated with a deterioration in the quality of life. Minet et al" randomised 81 patients with inoperable nonsmall cell lung cancer to receive either radiotherapy plus chemotherapy or radiotherapy alone and used the Karnofsky index to assess the quality of survival. No difference in score between the groups was seen and there was no actual survival advantage for either treatment.
Similar results were reported by Kaasa et at" and Kaasa and Mastekaasa'4 in a study of 95 patients with non-small cell lung cancer randomised to receive chemotherapy (cisplatin and etoposide) or radiography (2-8 Gy x 15). Quality of life was assessed with a locally developed questionnaire covering psychosocial wellbeing, disease and treatment related symptoms, physical function, and everyday activity. The tumour response rate in the radiotherapy group (42%) was double that in the chemotherapy arm but overall survival in the two groups was identical. After two weeks of treatment there was a significant drop in performance for the patients having chemotherapy, presumably reflecting the toxicity of treatment. Subsequently there were no differences in quality of life between the two groups. Of interest was the fact that psychosocial wellbeing correlated closely with disease related symptoms (anorexia, tiredness, pain) but poorly with treatment related effects (nausea, vomiting, alopecia, dysphagia). Thus patients recognised the signs of improvement and worsening of their disease and this was reflected in their wellbeing; but they may have accepted side effects of treatment as the price to pay for a chance of overcoming their cancer, and consequently this had less impact on 
SURGERY
Resection still offers the best chance of cure in patients with lung cancer, but what is their quality of survival and can the surgeon provide any palliation for patient found to be unresectable at thoracotomy? These were the questions addressed by the one major report on quality of life in patients having surgery. 45 The authors used the Carlens Vitagram to assess the quality of survival. This method has been validated in lung cancer.' The quality of survival in patients cured by resection was excellent. The patients who had an operation but subsequently died of the disease did not have a better quality of survival than non-surgically treated patients with the same stage of disease. The authors concluded that an operation had no palliative effect and the possible benefits of "reducing the tumour burden" could be dismissed. This important finding requires further verification by the more sophisticated methods now available for assessing quality of life.
Conclusions
Most patients with lung cancer are treated with palliative intent, where, by definition, the focus is on the quality rather than merely the duration of survival, yet relatively few studies report data on quality of life.
Substantial progress has been made in defining the concept of health related quality of life to allow agreement about what is to be assessed. An impressive range of practically useful measures has now been developed for collecting data about patients' subjective experience of disease and treatment in a reliable and valid way. Of particular interest is the modular assessment strategy, whereby a generic measure for patients with cancer can be supplemented by a standardised scale specifically relevant to lung cancer.
Work is continuing to show how quality control in collection of data on quality of life can best be achieved and to address problems that can arise in data analysis in longitudinal studies where there are problems of attrition. Sufficient progress has been made to suggest that assessment of quality of life should be included in the audit of clinical practice and evaluating treatment outcomes in clinical trials. The data obtained could provide an objective basis for informing decision making for individual patients and for making the case for allocation of appropriate resources to medical and supportive services.4748
